(Circulation. 1995;92:790-795.)
© 1995 American Heart Association, Inc.
Articles |
Carcinoid Heart Disease
Correlation of High Serotonin Levels With Valvular Abnormalities Detected by Cardiac Catheterization and Echocardiography
From the Divisions of Cardiology, Duke University Medical Center, Durham, NC, and the Division of Internal Medicine, Durham (NC) VA Medical Center.
Correspondence to Thomas M. Bashore, MD, Duke University Medical Center, PO Box 3012, Durham, NC 27710.
Background Although serotonin has been postulated as an etiologic agent in the development of carcinoid heart disease, no direct evidence for different ambient serotonin levels in cardiac and noncardiac patients has been reported to date.
Methods and Results The present study reviews our experience with 604 patients in the Duke Carcinoid Database. Nineteen patients with proven carcinoid heart disease (by cardiac catheterization and/or echocardiogram) were compared with the remaining 585 noncardiac patients in the database with regard to circulating serotonin and its principal metabolite, 5-hydroxyindole acetic acid (5-HIAA). No significant demographic differences existed between the cardiac and noncardiac groups; however, typical carcinoid syndrome symptoms (ie, flushing and diarrhea) were almost threefold more common in the cardiac group (P<.001). Compared with the noncardiac group, heart disease patients demonstrated strikingly higher (P<.0001) mean serum serotonin (9750 versus 4350 pmol/mL), plasma serotonin (1130 versus 426 pmol/mL), platelet serotonin (6240 versus 2700 pmol/mg protein), and urine 5-HIAA (219 versus 55.3 mg/24 h) levels. The spectrum of heart disease among the 19 patients showed a strong right-sided valvular predominance, with tricuspid regurgitation being the most common valvular dysfunction (92% by cardiac catheterization; 100% by echocardiogram).
Conclusions These data suggest that serotonin plays a major role in the pathogenesis of the cardiac plaque formation observed in carcinoid patients.
Key Words: serotonin • heart diseases • valves
This article has been cited by other articles:
 |
|
 |
|
  2006 WRITING COMMITTEE MEMBERS, R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, et al. 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons Circulation, October 7, 2008; 118(15): e523 - e661. [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Townsend, J. L. Wrana, G. E. Davis, and J. V. Barnett Transforming Growth Factor-{beta}-stimulated Endocardial Cell Transformation Is Dependent on Par6c Regulation of RhoA J. Biol. Chem., May 16, 2008; 283(20): 13834 - 13841. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Zolkowska, M. H. Baumann, and R. B. Rothman Chronic Fenfluramine Administration Increases Plasma Serotonin (5-Hydroxytryptamine) to Nontoxic Levels J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 791 - 797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bhattacharyya, J. Davar, G. Dreyfus, and M. E. Caplin Carcinoid Heart Disease Circulation, December 11, 2007; 116(24): 2860 - 2865. [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-J. Liang, L.-P. Lai, B.-W. Wang, S.-J. Juang, C.-M. Chang, J.-G. Leu, and K.-G. Shyu Mechanical stress enhances serotonin 2B receptor modulating brain natriuretic peptide through nuclear factor-{kappa}B in cardiomyocytes Cardiovasc Res, November 1, 2006; 72(2): 303 - 312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al. ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons J. Am. Coll. Cardiol., August 1, 2006; 48(3): e1 - e148. [Full Text] [PDF]
|
|
|
|
|
|
D. Zolkowska, R. B. Rothman, and M. H. Baumann Amphetamine Analogs Increase Plasma Serotonin: Implications for Cardiac and Pulmonary Disease J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 604 - 610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Poirier, T. D. Giles, G. A. Bray, Y. Hong, J. S. Stern, F. X. Pi-Sunyer, and R. H. Eckel Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss: An Update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease From the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism Circulation, February 14, 2006; 113(6): 898 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mekontso-Dessap, F. Brouri, O. Pascal, P. Lechat, N. Hanoun, L. Lanfumey, I. Seif, N. Benhaiem-Sigaux, M. Kirsch, M. Hamon, et al. Deficiency of the 5-Hydroxytryptamine Transporter Gene Leads to Cardiac Fibrosis and Valvulopathy in Mice Circulation, January 3, 2006; 113(1): 81 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Moller, P. A. Pellikka, A. M. Bernheim, H. V. Schaff, J. Rubin, and H. M. Connolly Prognosis of Carcinoid Heart Disease: Analysis of 200 Cases Over Two Decades Circulation, November 22, 2005; 112(21): 3320 - 3327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Tintner, P. Manian, P. Gauthier, and J. Jankovic Pleuropulmonary Fibrosis After Long-term Treatment With the Dopamine Agonist Pergolide for Parkinson Disease Arch Neurol, August 1, 2005; 62(8): 1290 - 1295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. I. Gustafsson, K. Tommeras, I. Nordrum, J. P. Loennechen, A. Brunsvik, E. Solligard, R. Fossmark, I. Bakke, U. Syversen, and H. Waldum Long-Term Serotonin Administration Induces Heart Valve Disease in Rats Circulation, March 29, 2005; 111(12): 1517 - 1522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Zuetenhorst and B. G. Taal Metastatic Carcinoid Tumors: A Clinical Review Oncologist, February 1, 2005; 10(2): 123 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Baseman, P. E. O'Suilleabhain, S. C. Reimold, S. R. Laskar, J. G. Baseman, and R. B. Dewey Jr Pergolide use in Parkinson disease is associated with cardiac valve regurgitation Neurology, July 27, 2004; 63(2): 301 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Kaltsas, G. M. Besser, and A. B. Grossman The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors Endocr. Rev., June 1, 2004; 25(3): 458 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Cote, E. Thevenot, C. Fligny, Y. Fromes, M. Darmon, M.-A. Ripoche, E. Bayard, N. Hanoun, F. Saurini, P. Lechat, et al. Disruption of the nonneuronal tph1 gene demonstrates the importance of peripheral serotonin in cardiac function PNAS, November 11, 2003; 100(23): 13525 - 13530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Nebigil and L. Maroteaux Functional Consequence of Serotonin/5-HT2B Receptor Signaling in Heart: Role of Mitochondria in Transition Between Hypertrophy and Heart Failure? Circulation, August 19, 2003; 108(7): 902 - 908. [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Moller, H. M. Connolly, J. Rubin, J. B. Seward, K. Modesto, and P. A. Pellikka Factors Associated with Progression of Carcinoid Heart Disease N. Engl. J. Med., March 13, 2003; 348(11): 1005 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Jian, J. Xu, J. Connolly, R. C. Savani, N. Narula, B. Liang, and R. J. Levy Serotonin Mechanisms in Heart Valve Disease I: Serotonin-Induced Up-Regulation of Transforming Growth Factor-{beta}1 via G-Protein Signal Transduction in Aortic Valve Interstitial Cells Am. J. Pathol., December 1, 2002; 161(6): 2111 - 2121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Xu, B. Jian, R. Chu, Z. Lu, Q. Li, J. Dunlop, S. Rosenzweig-Lipson, P. McGonigle, R. J. Levy, and B. Liang Serotonin Mechanisms in Heart Valve Disease II: The 5-HT2 Receptor and Its Signaling Pathway in Aortic Valve Interstitial Cells Am. J. Pathol., December 1, 2002; 161(6): 2209 - 2218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Connolly, H. V. Schaff, C. J. Mullany, M. D. Abel, and P. A. Pellikka Carcinoid Heart Disease: Impact of Pulmonary Valve Replacement in Right Ventricular Function and Remodeling Circulation, September 24, 2002; 106(12_suppl_1): I-51 - I-56. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Humbert, Z. Deng, G. Simonneau, R.J. Barst, O. Sitbon, M. Wolf, N. Cuervo, K.J. Moore, S.E. Hodge, J.A. Knowles, et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives Eur. Respir. J., September 1, 2002; 20(3): 518 - 523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Elangbam, K. A. Colman, R. M. Lightfoot, R. D. Tyler, and H. G. Wall Endocardial Myxomatous Change in Harlan Sprague-Dawley Rats (Hsd:S--D) and CD-1 Mice: Its Microscopic Resemblance to Drug-Induced Valvulopathy in Humans Toxicol Pathol, June 1, 2002; 30(4): 483 - 491. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Tomita and Q. Zhao Autopsy Findings of Heart and Lungs in a Patient With Primary Pulmonary Hypertension Associated With Use of Fenfluramine and Phentermine Chest, February 1, 2002; 121(2): 649 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Connolly, H. V. Schaff, C. J. Mullany, J. Rubin, M. D. Abel, and P. A. Pellikka Surgical Management of Left-Sided Carcinoid Heart Disease Circulation, September 18, 2001; 104(90001): I-36 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Nebigil, P. Hickel, N. Messaddeq, J.-L. Vonesch, M. P. Douchet, L. Monassier, K. Gyorgy, R. Matz, R. Andriantsitohaina, P. Manivet, et al. Ablation of Serotonin 5-HT2B Receptors in Mice Leads to Abnormal Cardiac Structure and Function Circulation, June 19, 2001; 103(24): 2973 - 2979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Rothman, M. H. Baumann, J. E. Savage, L. Rauser, A. McBride, S. J. Hufeisen, and B. L. Roth Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications Circulation, December 5, 2000; 102(23): 2836 - 2841. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Prasad, M. Mehra, M. Park, R. Scott, P. A. Uber, and P. M. McFadden Cardiac allograft valvulopathy: a case of donor-anorexigen-induced valvular disease Ann. Thorac. Surg., November 1, 1999; 68(5): 1840 - 1841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Burger, H. B. Sherman, M. J. Charlamb, J. Kim, L. A. Asinas, S. R. Flickner, and G. L. Blackburn Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months J. Am. Coll. Cardiol., October 1, 1999; 34(4): 1153 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Higenbottam, H. Marriott, G. Cremona, E. Laude, and D. Bee The Acute Effects of Dexfenfluramine on Human and Porcine Pulmonary Vascular Tone and Resistance Chest, October 1, 1999; 116(4): 921 - 930. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Biswas, C. L. Donovan, J. M. Forbess, S. H. Royal, and K. P. Landolfo Valve replacement for appetite suppressant-induced valvular heart disease Ann. Thorac. Surg., June 1, 1999; 67(6): 1819 - 1822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Kulke and R. J. Mayer Carcinoid Tumors N. Engl. J. Med., March 18, 1999; 340(11): 858 - 868. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Egermayer, G I. Town, and A. J Peacock Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension Thorax, February 1, 1999; 54(2): 161 - 168. [Full Text]
|
|
|
|
|
|
A. P. Fishman Aminorex to Fen/Phen : An Epidemic Foretold Circulation, January 12, 1999; 99(1): 156 - 161. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Khan, C. A. Herzog, J. V. St. Peter, G. G. Hartley, R. Madlon-Kay, C. D. Dick, R. W. Asinger, and J. T. Vessey The Prevalence of Cardiac Valvular Insufficiency Assessed by Transthoracic Echocardiography in Obese Patients Treated with Appetite-Suppressant Drugs N. Engl. J. Med., September 10, 1998; 339(11): 713 - 718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Thompson, X. Kurz, A. Van Ermen, S. Rasmussen, B. C. Corya, R. D. Glassman, B. Redmon, S. Raatz, J. P. Bantle, F. W. Wolff, et al. Valvular Heart Disease Associated with Fenfluramine-Phentermine N. Engl. J. Med., December 11, 1997; 337(24): 1772 - 1776. [Full Text]
|
|
|
|
|
|
H. M. Connolly, J. L. Crary, M. D. McGoon, D. D. Hensrud, B. S. Edwards, W. D. Edwards, and H. V. Schaff Valvular Heart Disease Associated with Fenfluramine-Phentermine N. Engl. J. Med., August 28, 1997; 337(9): 581 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Kushwaha, J. T. Fallon, and V. Fuster Restrictive Cardiomyopathy N. Engl. J. Med., January 23, 1997; 336(4): 267 - 276. [Full Text] [PDF]
|
|